Presented here is the latest breakthrough in immunopeptidomics by Wahle et al. from the Mann lab. The Innovative Immunopeptidomics by Biotinylated Antibodies and Streptavidin (IMBAS-MS) workflow. This cutting-edge technology offers an automated, highly sensitive, and cost-effective solution for researchers. IMBAS-MS empowers you to quantify over 5000 HLA class I peptides using just 200 μl of plasma in a mere 30 minutes.

IMBAS-MS simplifies the immunopeptidomics process by replacing the traditional ProteinA/G affinity capture with the highly specific streptavidin-biotin interaction, significantly reducing hands-on time. Whether you’re in a specialized immunopeptidomics lab or a mass spectrometry-focused facility, IMBAS-MS is accessible and efficient.

Discover the broader applications of sHLA immunopeptidomics, from enhancing our understanding of immune mechanisms to advancing precision oncology research. With its minimal-invasive nature and streamlined workflow, IMBAS-MS holds promise for disease monitoring and personalized medicine, potentially enabling earlier interventions and more effective treatments. Explore the world of IMBAS-MS and its impact on immunology and clinical research today.

Published in Molecular & Cellular Proteomics

Authors

M. Wahle; M. Thielert; M. Zwiebel; P. Skowronek; W.-F. Zeng; M. Mann

Title

IMBAS-MS Discovers Organ-Specific HLA Peptide Patterns in Plasma